Objective To explore the clinical effect of "Feiyan Yihao" Chinese medicine granules in the treatment of cases of COVID-19.
Methods A total of 98 patients with COVID-19 who were non-critical were collected and divided into a treatment group (55 cases) and a control group (43 cases) according to random number method. The control group was given conventional oxygen therapy, antiviral, anti-inflammatory, phlegm and other treatments. The treatment group was given "Feiyan Yihao" granules on the basis of the control group. TCM syndrome score, laboratory data, and total hospitalization days were compared between the two groups of patients before and after treatment.
Results In terms of TCM syndrome score: the treatment group decreased from (16.44± 8.2) points to (4.20 ±4.3) points, and the control group decreased from (17.56± 8.3) points to (7.81 ±5.2) points. There was a statistical difference in groups before and after treatment ( P<0.05), and between the groups after treatment ( P<0.05). At the same time, the effective component ratio of the TCM syndrome scores in the treatment group was significantly better than that in the control group ( P<0.05). In terms of laboratory indicators: after treatment, the patient's lymphocyte absolute count (LYM) increased, D-dimer (D-Dimer) and blood lactate dehydrogenase (LDH) decreased. Comparing before and after treatment, LYM and D-Dimer were statistically different in both groups ( P<0.05), while LDH was only statistically different in the treatment group ( P<0.05). The treatment group could rincrease of blood LYM ( P<0.05) and reduce increase of blood LDH ( P<0.05), and shorten the days of hospital stays ( P<0.05).
Conclusion "Feiyan Yihao" granules can improve TCM syndromes and laboratory indicators, and shorten the duration of hospitalization on patients with COVID-19. It has good clinical efficacy and is worthy of clinical popularization.
摘要：目的 探讨“肺炎1号方”中药颗粒剂治疗新型冠状病毒肺炎的临床疗效 。方法 收集确诊住院的非危重型 新型冠状病毒肺炎患者98例，按照随机数字法分为治疗组(55例）和对照组(43例），对照组给予常规氧疗、抗病毒、抗 炎、化痰等治疗，治疗组在对照组基础上口服“肺炎1号方”颗粒。比较两组患者用药前后的中医证候积分、实验室指标 及总住院时间。 结果 治疗组和对照组治疗前后中医证候积分分别为（16.44±8.2)分和（17.56±8.3)分、(4.20±4.3)分和 (7.81±5.2)分，组内治疗前后比较差异均有统计学意义( P<0.05)，治疗组和对照组治疗后比较差异有统计学意义( P< 0.05)。同时治疗组中医证候积分的有效率构成比显著优于对照组( P<0.05);治疗组治疗后患者淋巴细胞计数(LYM) 上升、D-二聚体(D-Dimer)下降、血乳酸脱氢酶(LDH)下降，LYM和D-Dimer在组内治疗前后比较差异均有统计学意义 ( P<0.05)，LDH仅在治疗组中差异有统计学意义( P<0.05)。治疗组可上调血LYM( P<0.05)及减轻血LDH的上升幅度 ( P<0.05)，同时缩短住院天数( P<0.05)。 结论 “肺炎1号方”颗粒能改善新型冠状病毒肺炎患者的中医证候和实验室 指标，缩短住院病程，具有良好的临床疗效，值得临床推广使用。